Lercanidipine Hydrochloride Torrent Pharma (Uk)

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Hydrochloride Torrent Pharma (Uk), is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure.

GNH USA supplies Lercanidipine Hydrochloride Torrent Pharma (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Hydrochloride is a dihydropyridine calcium channel blocker used in the management of high blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in adults with essential hypertension. - Primary hypertension: helps achieve target blood pressure levels when lifestyle measures are insufficient. - Controlled hypertension: maintains stable blood pressure when combined with other antihypertensive agents.

Lercanidipine Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: sensation of warmth and redness, typically on the face or neck. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: light‑headed feeling, especially when standing quickly. - Tachycardia: increased heart rate without accompanying chest pain.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Myocardial infarction: rare occurrence of heart attack symptoms. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Blood dyscrasias: unexplained bruising or low blood cell counts.

Before initiating therapy with Lercanidipine Hydrochloride, consider the following safety measures.

- Blood pressure monitoring: regularly assess to ensure therapeutic response and avoid excessive lowering. - Hepatic impairment: use with caution in patients with liver dysfunction, adjusting dose if necessary. - Elderly patients: start at the lowest effective dose and monitor for orthostatic effects. - Concomitant antihypertensives: watch for additive blood pressure reductions. - Severe aortic stenosis: contraindicated due to risk of reflex tachycardia. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of hypotension. - Other calcium channel blockers: additive vasodilatory effects can lead to excessive blood pressure drop. - Grapefruit juice: can raise drug levels, enhancing adverse effects.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypotensive response; monitor electrolytes. - ACE inhibitors or ARBs: combined effect on blood pressure requires careful titration. - Beta‑blockers: monitor heart rate and blood pressure for synergistic effects. - NSAIDs: may reduce antihypertensive efficacy. - Digoxin: monitor for signs of toxicity due to altered renal clearance.